Beida Pharmaceuticals: Approval for clinical trials of erlotinib hydrochloride tablets for adjuvant therapy in high-risk stage IA2 to IB after surgery.

Baide Pharmaceutical announced that the company has received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The clinical trial application for the use of Erlotinib Hydrochloride tablets in adjuvant therapy for stage IA2 high-risk to IB non-small cell lung cancer patients with EGFR gene sensitive mutations after surgery has been approved.